Trial Profile
Targeting Beta Cell Dysfunction in Longstanding T1D
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 27 Jan 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- 21 Jan 2022 Status changed from recruiting to completed.
- 20 Jul 2021 Planned End Date changed from 1 Jun 2020 to 1 Dec 2021.
- 20 Jul 2021 Planned primary completion date changed from 1 Apr 2020 to 1 Dec 2021.